The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
SAN DIEGO, March 16, 2022 /3BL Media/ -- Illumina, Inc. (NASDAQ:ILMN) announced the launch of TruSight™ Oncology (TSO) Comprehensive (EU), a single test that assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. With its global launch first taking place in Europe, the in vitro diagnostic (IVD) kit will help inform precision medicine decisions for cancer patients across the continent.
Partnership will expand use of next-generation sequencing (NGS) to help diagnose patients quickly and more accurately.
NEW DELHI, March 15, 2022 /3BL Media/ - Illumina Singapore, subsidiary of Illumina Inc (NASDAQ: ILMN) and Trivitron Healthcare, one of India's largest medical technology companies, have entered into a strategic partnership to develop and expand the use of next-generation sequencing (NGS)-based in-vitro diagnostic tests (IVD) in India.
Shannon Whitmore is a Real Time Revolutionary who has been driving the field of scientific computing ever since developing a tool for visualizing the secondary structure of rRNA for her master's thesis.
Illumina’s innovations transcend beyond improving the health of humans to improving the health of all living things. Our technology is being used to support the biodiversity of our planet in numerous ways, including:
Recognizing and supporting rare disease organizations and families around the world
Multimedia with summary
On February 28th, and everyday, Illumina recognizes Rare Disease Day 2022. Throughout the entire month of February, we highlighted various organizations that support and advocate for patients and families impacted by rare genetic disorders.
NoRo pilots the country’s first and only patient-run reference center for rare diseases
In 2007, Dorica Dan, the mother of a child with the rare disease Prader Willi Syndrome, envisioned the first and only patient-run reference center for rare diseases in Europe. It would help patients and families with the decisions and therapies that are needed after receiving their diagnosis.